New CoreValve Data Featured In TCT Late-Breaking Clinical Trials
This article was originally published in The Gray Sheet
Executive Summary
Data on Medtronic’s CoreValve transcatheter aortic valve replacement device will headline this year’s Transcatheter Cardiovascular Therapeutics conference, joined by data on biodegradable drug-eluting stents, as well as drug-coated balloon results, in the late-breaking trial sessions.
You may also be interested in...
Research In Brief
MRI screening finds spinal fungal infections. Inappropriate ICD shock rates are same in elderly and younger patients.
Medtronic, Bard In Close Race To First FDA-Approved Drug-Eluting Balloon
Medtronic says it reached the necessary trial enrollment to support PMA approval for its IN.PACT Admiral drug-eluting balloon catheter to treat atherosclerosis in the superficial femoral artery. On the same day, CR Bard said it was prepared to submit its final PMA module for its Lutonix drug-eluting balloon by year’s end.
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.